Press Releases

Archives: Search / 2017

2016201520142013201220112010200920082007

2014 Archives

Dec 5, 2014
-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters --

Eisai Inc. announced today that 16 abstracts highlighting new data on perampanel and rufinamide will be presented at the 68th Annual American Epilepsy Society (AES) meeting, taking place in...

More
Dec 1, 2014
FOR U.S. MEDIA ONLY

Eisai announced the presentation of six abstracts at the 2014 San Antonio Breast Cancer Symposium (SABCS), highlighting new data for eribulin mesylate and netupitant/palonosetron (NEPA). The...

More
Nov 17, 2014

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that Eisai has been ranked 11th among the world's leading pharmaceutical companies in the Access to Medicine Index...

More
Nov 6, 2014
Celebrity Animal Behaviorist Brandon McMillan Joins Eisai, Epilepsy Foundation and 4 Paws for Ability to Shed Light on How Dogs Can Provide Functional and Emotional Support

Eisai Inc. today announced the launch of Magnolia™ Paws for Compassion™, a new program created to raise awareness of the beneficial impact that animals can have on people living with epilepsy...

More
Nov 6, 2014
-- Lorcaserin Evaluated for Effect on the NASH Clinical Score: A Retrospective Analysis of Three Phase 3 Studies --

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the...

More
Nov 3, 2014
-- Trial Met Primary Efficacy Endpoint with Statistical Significance After 12 Weeks of Treatment --

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking...

More
Oct 31, 2014
-- Results of Investigational Study of Coadministration of Lorcaserin and Phentermine Accepted as Late Breaking Poster --

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data for BELVIQ® (lorcaserin HCl) CIV will be presented during ObesityWeekSM hosted by The Obesity Society and the...

More
Oct 28, 2014
-- Trial Met Primary Safety Objective After 12 Weeks of Treatment -- -- Data to be Presented at The Obesity Society 2014 Annual Meeting During ObesityWeekSM --

WOODCLIFF LAKE, NJ and SAN DIEGO, CA, October 28, 2014 – Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results of a pilot study to assess the safety of...

More
Oct 20, 2014

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor...

More
Oct 14, 2014

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's sNDA for rufinamide and granted it priority review designation as an adjunctive treatment of...

More
Oct 14, 2014

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its in-house developed agent lenvatinib mesylate (lenvatinib)...

More
Oct 13, 2014
Recognizing unique patient needs on Metastatic Breast Cancer Awareness Day, mbcInfoCenter.com offers important metastatic breast cancer resources in one convenient place

Woodcliff Lake, NJ, October 13, 2014 / PR Newswire / — Understanding the burden of metastatic breast cancer (MBC), and the toll it takes on patients and their loved ones, Eisai Inc....

More
Oct 13, 2014

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...

More
Oct 13, 2014
-- First New Fixed Combination Targeting Two Critical Pathways Involved in CINV --

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and...

More
Oct 10, 2014

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ® (lorcaserin HCl) was...

More
Oct 1, 2014
Findings suggest need for improved education efforts within epilepsy community and beyond to address misperceptions about the disease

Results from a national survey conducted by Eisai Inc., in partnership with the Epilepsy Foundation, found that the vast majority (95%) of epilepsy patients and caregivers believe the public is...

More
Sep 10, 2014

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...

More
Sep 3, 2014

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into an agreement with Concordia Pharmaceuticals Inc. ("Concordia"), a subsidiary of Concordia...

More
Jun 26, 2014

Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed-dose combination of netupitant and palonosetron being...

More
Jun 23, 2014
Those Who Take Steps Report Greater Satisfaction with Weight Loss Medications and Surgical Procedures

An analysis of data from the 2012 U.S. National Health and Wellness Survey showed that the majority of those affected by obesity are not taking steps to lose weight (58.4%). The analysis of more...

More
Jun 23, 2014

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Barry Lederman to the position of Vice President and Chief Financial Officer (CFO)....

More
Jun 16, 2014

Eisai Inc. announced today that a Phase III clinical trial (study 332) of its in-house-discovered AMPA receptor antagonist perampanel has met its primary endpoint in patients with primary...

More
Jun 13, 2014
Pre-Game Activities Honor Local Epilepsy Awareness Ambassadors

Eisai Inc. announced today it has become a "Keeper of the Flame" sponsor of the Epilepsy Foundation of Metropolitan New York's 2nd Annual Epilepsy Awareness Day which will take place during a...

More
Jun 9, 2014

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...

More
May 31, 2014
Phase III data for lenvatinib to be presented at ASCO

Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive...

More
 

print email rss